Sletten, Arthur C.
Davidson, Jessica W.
Yagabasan, Busra http://orcid.org/0000-0003-4351-6165
Moores, Samantha
Schwaiger-Haber, Michaela http://orcid.org/0000-0002-2715-753X
Fujiwara, Hideji
Gale, Sarah
Jiang, Xuntian
Sidhu, Rohini
Gelman, Susan J.
Zhao, Shuang
Patti, Gary J. http://orcid.org/0000-0002-3748-6193
Ory, Daniel S.
Schaffer, Jean E. http://orcid.org/0000-0002-4954-6659
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK064989, F30 DK120141, P30 DK020579, P30 DK036836, R01 DK108357)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32 HL007275)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM07200)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Article History
Received: 22 September 2020
Accepted: 6 August 2021
First Online: 1 September 2021
Change Date: 24 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-27255-y
Competing interests
: Daniel Ory and Rohini Sidhu work for and hold equity in Casma Therapeutics, a company whose goal is to develop therapeutics that target the autophagy pathway for treatment of diseases that include non-alcoholic fatty liver disease. All remaining authors declare no competing interests.